Débute à 
A-2553
1375 avenue Thérèse-Lavoie-Roux (Aile A)
(QC) Canada

Exploratory Innovations as a Path to the Lab of the Future. New Technology Applications for API Development

Dr. Frederic Buono – Senior Associate Director – Chemical Development US- RDG. Boehringer-Ingelheim Pharmaceuticals.

In recent years, the landscape of process development has undergone a significant transformation due to the introduction of cutting-edge technologies. Innovations such as automation, robotics, and machine learning have had a profound impact on the drug and process developments. Our daily workflows can be automated while also being substantially improved. To deliver value to the business and patients by accelerating the development of novel therapeutics, we primarily focus on the development of an eco-design of the shortest and highest-yielding synthetic routes for green, cost-effective, and fast API development using innovative science and technologies. From these technologies, we can count on applications of catalytic reactions, flow reactions and biocatalysis. Simultaneously, we are exploring game-changing, disruptive, and digital technologies to transform chemistry operations for the future (e.g. digitalization). Over the last few years, our group has implemented and integrated several technologies into our workflow and demonstrated their positive impacts on API deliveries, supporting drug discovery and development. Our emphasis on mechanistic and kinetic studies for chemical reaction is crucial for understanding and optimizing the processes, and to contribute to the success of APIs production on a multi-kilogram scale for several R&D projects. Innovation and incorporation of these technologies are key steps forward advancing the Lab of the Future in pharmaceutical research and development.

Conférence avec Dr. Frederic Buono de Boehringer Ingelheim